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BACKGROUND
Whether a restrictive threshold for hemoglobin level in red-cell transfusions, as 
compared with a liberal threshold, reduces postoperative morbidity and health 
care costs after cardiac surgery is uncertain.
METHODS
We conducted a multicenter, parallel-group trial in which patients older than 16 years 
of age who were undergoing nonemergency cardiac surgery were recruited from 
17 centers in the United Kingdom. Patients with a postoperative hemoglobin level 
of less than 9 g per deciliter were randomly assigned to a restrictive transfusion 
threshold (hemoglobin level <7.5 g per deciliter) or a liberal transfusion threshold 
(hemoglobin level <9 g per deciliter). The primary outcome was a serious infection 
(sepsis or wound infection) or an ischemic event (permanent stroke [confirmation 
on brain imaging and deficit in motor, sensory, or coordination functions], myo-
cardial infarction, infarction of the gut, or acute kidney injury) within 3 months 
after randomization. Health care costs, excluding the index surgery, were estimated 
from the day of surgery to 3 months after surgery.
RESULTS
A total of 2007 patients underwent randomization; 4 participants withdrew, leav-
ing 1000 in the restrictive-threshold group and 1003 in the liberal-threshold group. 
Transfusion rates after randomization were 53.4% and 92.2% in the two groups, 
respectively. The primary outcome occurred in 35.1% of the patients in the restric-
tive-threshold group and 33.0% of the patients in the liberal-threshold group (odds 
ratio, 1.11; 95% confidence interval [CI], 0.91 to 1.34; P = 0.30); there was no indi-
cation of heterogeneity according to subgroup. There were more deaths in the re-
strictive-threshold group than in the liberal-threshold group (4.2% vs. 2.6%; hazard 
ratio, 1.64; 95% CI, 1.00 to 2.67; P = 0.045). Serious postoperative complications, 
excluding primary-outcome events, occurred in 35.7% of participants in the re-
strictive-threshold group and 34.2% of participants in the liberal-threshold group. 
Total costs did not differ significantly between the groups.
CONCLUSIONS
A restrictive transfusion threshold after cardiac surgery was not superior to a liberal 
threshold with respect to morbidity or health care costs. (Funded by the National 
Institute for Health Research Health Technology Assessment program; Current 
Controlled Trials number, ISRCTN70923932.)
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Perioperative anemia is common after cardiac surgery and is associated with sig-nificant increases in morbidity and mortal-
ity.1-3 The transfusion of allogeneic red cells is 
the preferred treatment for acute anemia and is 
also used in patients undergoing cardiac surgery; 
typically, more than 50% of patients receive a 
perioperative transfusion,4,5 which uses a substan-
tial proportion of blood supplies.6
Observational studies suggest that transfusion 
is harmful after cardiac surgery; associations 
have been reported between transfusion and in-
fection, low cardiac output, acute kidney injury, 
and death.2,7,8 In contrast, randomized, controlled 
trials of red-cell transfusion with restrictive thresh-
olds (i.e., transfusions at lower hemoglobin levels) 
versus more liberal thresholds (transfusions at 
higher hemoglobin levels) in a range of acute care 
and surgical settings have shown no significant 
differences between the two approaches with 
respect to adverse events or 30-day mortality.9 
These findings, combined with increasing demands 
on blood services10 and the costs of storing, han-
dling, and administering red-cell units,11 have 
led to an emphasis on restrictive transfusion 
thresholds in contemporary blood-management 
guidelines12-14 and in health policy statements.15,16
Nevertheless, uncertainty about a safe thresh-
old for restrictive red-cell transfusion in cardiac 
surgery persists and is reflected in the wide 
range of transfusion rates in cardiac centers in 
the United Kingdom (25 to 75%)5 and in the 
United States (8 to 93%).4 Uncertainty persists 
because previous trials comparing liberal and 
restrictive thresholds in cardiac surgery lacked 
adequate statistical power,17-21 and because other 
trials involved patients who have not undergone 
cardiac surgery and the results of those trials 
may not apply to patients with unstable cardio-
vascular disease.9,22 To address this uncertainty, 
we performed the Transfusion Indication Thresh-
old Reduction (TITRe2) trial to test the hypoth-
esis that a restrictive threshold for red-cell trans-
fusion, as compared with a liberal threshold, 
would reduce postoperative morbidity and health 
care costs.
Me thods
Trial Design and Oversight
TITRe2 was a multicenter, parallel-group, ran-
domized, controlled trial conducted at 17 cardi-
ac surgery centers in the United Kingdom. De-
tails of the methods have been reported previously.23 
The trial was funded by the National Institute for 
Health Research (NIHR) Health Technology As-
sessment program. A National Health Service 
research ethics committee approved the study, 
which was conducted in accordance with the prin-
ciples of the International Conference on Har-
monisation-Good Clinical Practice under the 
oversight of University Hospitals Bristol National 
Health Service Foundation Trust. The last author 
vouches for the data and the analyses and for the 
fidelity of this report to the study protocol (avail-
able with the full text of this article at NEJM.org).
Participants
Patients older than 16 years of age who were 
undergoing nonemergency cardiac surgery were 
eligible to participate; exclusion criteria23 are de-
scribed in Table S1 in the Supplementary Appen-
dix, available at NEJM.org. Participants provided 
written informed consent before surgery. If the 
hemoglobin level dropped below 9 g per deciliter 
(or the hematocrit fell below 27%) at any time 
after surgery, the participant was randomly as-
signed to a study group. Thresholds were expressed 
in terms of hemoglobin level or hematocrit; here-
inafter, hemoglobin threshold should be inter-
preted as a reference to either hemoglobin level or 
hematocrit.
Randomization
Patients were randomly assigned to either the 
liberal transfusion-threshold group (threshold 
hemoglobin level, 9 g per deciliter) or the restric-
tive transfusion-threshold group (threshold he-
moglobin level, 7.5 g per deciliter) by means of 
a secure Internet-based system that concealed 
assignments and used cohort minimization to 
balance assignments according to center and type 
of surgery. Physicians and nurses were aware of 
the group assignments. We intended participants 
to be unaware of the group assignments and 
tested our success in keeping the study groups 
blinded by asking the patients if they were aware 
of the group they were in.
Interventions
Participants in the liberal-threshold group re-
ceived a transfusion of 1 unit of red cells imme-
diately after randomization. An additional unit 
was transfused if the patient’s hemoglobin level 
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remained below 9 g per deciliter or dropped 
below 9 g per deciliter again during postopera-
tive hospitalization. In the restrictive-threshold 
group, 1 unit of red cells was transfused if the 
hemoglobin level dropped below 7.5 g per decili-
ter; a further unit was transfused if the level re-
mained below 7.5 g per deciliter or dropped below 
7.5 g per deciliter again during postoperative 
hospitalization.
Physicians could contravene the assigned 
threshold but had to document the reason for 
the contravention and record the hemoglobin 
level at the time of the contravention. Similarly, 
a physician could permanently discontinue ad-
herence to the assigned treatment threshold. 
This discontinuation did not constitute with-
drawal of the participant from the study, and we 
continued to collect outcome data in accordance 
with the protocol for all such participants and 
included them in the analysis population. Other 
aspects of postoperative care were carried out in 
accordance with the center’s usual practice. 
Follow-up consisted of contact with the partici-
pants by mail or telephone 3 months after ran-
domization to inquire whether a primary out-
come event or some other serious adverse event 
had occurred, to find out about health resources 
used since discharge, and to ask questions about 
general health status and participants’ aware-
ness of their random assignment.
Outcomes
The primary outcome was a composite of a seri-
ous infection (sepsis or wound infection24-26) or 
an ischemic event (permanent stroke, myocar-
dial infarction, infarction of the gut, or acute 
kidney injury27) within 3 months after random-
ization. Definitions and adjudication procedures 
are described in Table S2 in the Supplementary 
Appendix. An event was classified as “present” 
if it was recorded as having occurred, “absent” 
if it was confirmed that it had not occurred, and 
“missing” if it was not possible to confirm 
whether the event had occurred.
Several secondary outcomes were prespecified, 
including the number of units of red cells and 
other blood components transfused after ran-
domization; the occurrence of an infection (either 
sepsis or wound infection, as for the primary out-
come, but not including ischemic events); the oc-
currence of an ischemic event (permanent stroke, 
myocardial infarction, infarction of the gut, or 
acute kidney injury, as for the primary outcome, 
but not including infections); the duration of stay 
in the intensive care unit (ICU), a high-depen-
dency unit (in which care is less intensive than 
in an ICU but more intensive than in a hospital 
ward), or the hospital; and all-cause mortality. 
The presence of a clinically significant pulmo-
nary complication (defined according to the need 
for noninvasive ventilation, reintubation, or ven-
tilation or a tracheostomy) was added as a sec-
ondary outcome in an amendment to the protocol 
dated December 2, 2012. All serious adverse events 
that occurred during follow-up were document-
ed and coded in accordance with the Medical 
Dictionary for Regulatory Activities, version 14.1; adju-
dicators of adverse events were unaware of the 
group assignments.
General health status was assessed at 6 weeks 
and 3 months after surgery with the use of the 
EuroQol Group 5-Dimension Self-Report Ques-
tionnaire (EQ-5D).28 The EQ-5D measure of 
health-related quality of life consists of a descrip-
tive system, which can be converted into a single 
summary index score (ranging from −0.594 to 1), 
and a score on a visual-analogue scale (ranging 
from 0 to 100). For both the index score and the 
score on a visual-analogue scale, higher scores 
indicate better quality of life.
Adherence to the Protocol
Nonadherence was defined as either the failure 
to transfuse red cells within 24 hours after a 
patient’s hemoglobin fell below the assigned 
threshold or the administration of a transfusion 
when the hemoglobin level was above the as-
signed threshold. Multiple instances of nonadher-
ence could occur for one patient. An instance of 
nonadherence was considered to be severe when 
it changed the classification of a patient with re-
spect to receipt of any transfusion (i.e., when a 
patient’s hemoglobin level fell below the assigned 
threshold but the patient did not receive any 
transfusion or when a patient’s hemoglobin level 
never fell below the assigned threshold but the 
patient did receive a transfusion).
Cost Analysis
We performed a cost analysis in accordance with 
guidelines established in the United Kingdom by 
the National Institute for Health and Care Excel-
lence.29 Resources used in the hospital and up to 
3 months after surgery were documented, valued 
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Characteristic
Restrictive  
Transfusion Threshold  
(N = 1000)
Liberal  
Transfusion Threshold  
(N = 1003)
Preoperative
Age — yr
Median 69.9 70.8
Interquartile range 63.1–76.0 64.1–76.7
Male sex — no. (%) 693 (69.3) 680 (67.8)
Body-mass index† 28.2±5.0 28.2±4.9
EuroSCORE‡
Median 5.0 5.0
Interquartile range 3.0–7.0 3.0–7.0
NYHA class — no./ 
total no. (%)§
I 235/977 (24.1) 258/974 (26.5)
II 445/977 (45.5) 440/974 (45.2)
III 268/977 (27.4) 257/974 (26.4)
IV 29/977 (3.0) 19/974 (2.0)
CCS angina class — no./total no. (%)¶
No angina 365/982 (37.2) 353/980 (36.0)
I 169/982 (17.2) 193/980 (19.7)
II 273/982 (27.8) 253/980 (25.8)
III 139/982 (14.2) 142/980 (14.5)
IV 36/982 (3.7) 39/980 (4.0)
Coronary artery disease — no./total no. (%)
None 310/993 (31.2) 310/998 (31.1)
Single-vessel 112/993 (11.3) 113/998 (11.3)
Double-vessel 132/993 (13.3) 150/998 (15.0)
Triple-vessel 403/993 (40.6) 402/998 (40.3)
Not investigated 36/993 (3.6) 23/998 (2.3)
Stenosis >50% in left main stem — no./total no. (%) 159/987 (16.1) 145/990 (14.6)
Urgent operative priority — no. (%) 126 (12.6) 119 (11.9)
Diabetes — no. (%) 198 (19.8) 201 (20.0)
Hemofiltration or dialysis — no./total no. (%) 7/999 (0.7) 12/1002 (1.2)
Cerebrovascular accident or transient ischemic attack — no. (%) 76 (7.6) 87 (8.7)
Hemoglobin — g/dl 13.3±1.5 13.3±1.5
Estimated GFR — ml/min/1.73 m2
Median 74.5 72.8‖
Interquartile range 57.2–92.9 56.4–93.2
Intraoperative
Cardiac procedure — no. (%)
CABG only 408 (40.8) 408 (40.7)
Valve only 307 (30.7) 304 (30.3)
CABG and valve 195 (19.5) 203 (20.2)
Major aortic procedure 54 (5.4) 62 (6.2)
Table 1. Preoperative and Intraoperative Characteristics.*
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in 2012–2013 pounds sterling with the use of 
national sources30-33 (wherever possible the valu-
ations were based on actual costs rather than on 
charges), and converted to U.S. dollars (£1=$1.67). 
Resources included blood products and any re-
sources associated with complications (includ-
ing diagnostic tests), length of hospital stay, and 
various levels of care up to 3 months after surgery; 
the costs of the index surgery were not included. 
Further details of the cost analysis are provided 
in the Supplementary Appendix.
Statistical Analysis
Basing estimates on previous data2 and allowing 
for anticipated nonadherence to the assigned 
thresholds,23 we estimated that the frequency of 
the primary outcome in the group with the re-
strictive transfusion threshold would be approxi-
mately 11% and that the frequency in the group 
with the liberal threshold would be approxi-
mately 17%. We calculated that a sample size of 
1468 would be required for the study to have 90% 
power to detect this difference in a two-sided test, 
at a 5% level of significance. The target sample 
size was increased to 2000 to account for uncer-
tainty regarding the rate of nonadherence, since 
higher-than-expected rates of nonadherence would 
reduce the power.
All the analyses were performed on an inten-
tion-to-treat basis according to a prespecified 
analysis plan.34 Continuous data are summarized 
as means and standard deviations or as medians 
and interquartile ranges if distributions are 
skewed. All the analyses were based on mixed-
effects methods, with adjustment for the type of 
surgery as a fixed effect and center as a random 
effect (described as shared-frailty terms in time-
to-event models). Binary outcomes were ana-
lyzed with the use of logistic regression. Time-
to-event outcomes were analyzed with the use of 
Cox proportional-hazards models; data on dura-
tion of stay in the ICU, a high-dependency unit, 
and the hospital were censored at the time of a 
patient’s death, and data on the time to death 
were censored at the time of the last follow-up for 
survivors. EQ-5D scores were analyzed with the 
use of mixed-effects, mixed-distribution models.35
We compared the frequency of the primary 
outcome in prespecified subgroups by estimat-
ing the interaction between group assignment 
and subgroup variable. Sensitivity analyses were 
performed for the primary outcome (as described 
in the Supplementary Appendix) and for mortal-
ity. A 5% significance level (two-sided) was used 
in the analysis of the main treatment effects and 
in subgroup analyses, and a 10% significance 
level was used in the analysis of interactions be-
tween assigned group and time in longitudinal 
Characteristic
Restrictive  
Transfusion Threshold  
(N = 1000)
Liberal  
Transfusion Threshold  
(N = 1003)
Other procedure 36 (3.6) 26 (2.6)
Tranexamic acid used — no./total no. (%) 806/999 (80.7) 809/1002 (80.7)
Aprotinin used — no./total no. (%) 39/942 (4.1) 32/952 (3.4)
Blood-recovery system used — no./total no. (%) 481/999 (48.1) 503/1003 (50.1)
*  Plus–minus values are means ±SD. The restrictive transfusion threshold was less than 7.5 g per deciliter, and the liberal transfusion thresh-
old was less than 9 g per deciliter. There were no significant between-group differences at baseline. Details on other preoperative and intra-
operative characteristics are provided in Table S3 in the Supplementary Appendix. CABG denotes coronary-artery bypass grafting, and GFR 
glomerular filtration rate.
†  Data on body-mass index (the weight in kilograms divided by the square of the height in meters) were missing for one patient in the group 
with a liberal transfusion threshold.
‡  The European System for Cardiac Operative Risk Evaluation (EuroSCORE) allows the calculation of the risk of death after heart surgery. A 
score of 0 indicates the lowest level of risk and a score of 44 indicates the highest level of risk; a score of more than 5 is considered to indi-
cate a high risk. Data are missing for 17 patients in the group with a restrictive transfusion threshold and 21 patients in the group with a lib-
eral transfusion threshold.
§  New York Heart Association (NYHA) classes range from I to IV, with higher classes indicating worse condition.
¶  Canadian Cardiovascular Society (CCS) angina classes range from I to IV, with higher classes indicating greater limitations on physical activ-
ity owing to angina.
‖  Data were missing for two persons in this group.
Table 1. (Continued.)
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models. Likelihood-ratio tests were performed. 
No formal adjustment was made for multiple 
testing or for an interim analysis.23,34 All analy-
ses were performed with the use of Stata soft-
ware, version 12.1 or 13.1 (StataCorp), or SAS 
software, version 9.3 (SAS Institute).
R esult s
Study Population
Patients were screened for eligibility between 
July 2009 and February 2013; a total of 3565 con-
sented to take part in the study (Fig. S1 in the 
Supplementary Appendix), of whom 2007 under-
went randomization between July 15, 2009, and 
February 18, 2013. Four participants withdrew 
and requested that their data be excluded from 
the study. Therefore, the analysis population con-
sisted of 2003 participants — 1000 in the restric-
tive-threshold group and 1003 in the liberal-
threshold group.
The baseline characteristics were similar in 
the two groups (Table 1, and Table S3 in the 
Supplementary Appendix). The median age was 
70.3 years (interquartile range, 63.5 to 76.4), and 
68.5% were men. Most patients had undergone 
coronary-artery bypass grafting (40.7%) or valve 
surgery (30.5%). A total of 25.7% of the partici-
pants received a red-cell transfusion before ran-
domization (Table 2). The baseline characteris-
tics of patients who consented to participate but 
did not undergo randomization are shown in 
Table S4 in the Supplementary Appendix.
At discharge, 15.1% of patients believed that 
they knew which treatment they had received; 
75.6% of those patients (115 patients) were cor-
rect (Table S13 in the Supplementary Appendix). 
At 3 months after surgery, a greater number of 
patients (27.5%) thought that they knew which 
treatment they had received, but fewer (56.6%) 
were correct.
Hemoglobin Levels and Transfusions
After randomization, the mean nadir in the he-
moglobin level was approximately 1 g per decili-
ter lower in the group assigned to the restrictive 
threshold than in the group assigned to the 
liberal threshold (Fig. 1); 53.4% of those in the 
restrictive-threshold group and 92.2% in the 
liberal-threshold group received one or more 
transfusions (risk ratio, 0.58; 95% confidence 
interval [CI], 0.54 to 0.62, P<0.001) (Table 2, and 
Table S5 and Fig. S2A in the Supplementary Ap-
pendix). A median of 1 unit of red cells (inter-
quartile range, 0 to 2) was transfused in the re-
strictive-threshold group, and a median of 2 units 
(interquartile range, 1 to 3) were transfused in 
the liberal-threshold group. During the entire 
index admission, 63.7% of the patients in the 
restrictive-threshold group and 94.9% of those 
in the liberal-threshold group received transfu-
sions. The use of other blood products was 
similar in the two groups (Table 2, and Table S5 
and Fig. S2B in the Supplementary Appendix). 
The rate of severe nonadherence was 9.7% in the 
restrictive-threshold group and 6.2% in the lib-
eral-threshold group, and the rates of any non-
adherence were 30.0% and 45.2%, respectively 
(Table 2).
Outcomes
Outcome data at 3 months after randomization 
were not obtained for 25 participants (1.2%) 
(Fig. S1 in the Supplementary Appendix). The 
numbers of patients with data for each outcome 
analysis are shown in Table S6 in the Supple-
mentary Appendix; for the primary outcome 
analysis overall, data were missing for 97 of 2003 
participants (4.8%). The primary outcome was 
observed in 35.1% of the patients in the restric-
tive-threshold group and 33.0% of the patients 
in the liberal-threshold group (odds ratio, 1.11; 
95% CI, 0.91 to 1.34; P = 0.30) (Table 3, and Fig. 
S3 in the Supplementary Appendix). The major-
ity of primary outcome events in each group 
occurred before hospital discharge (Table S7 in 
the Supplementary Appendix). The Supplemen-
tary Appendix includes additional details regard-
ing the primary outcome, including the reasons 
for missing data (Table S6), the distribution of 
primary-outcome events before and after hospi-
tal discharge (Table S7), and a Kaplan–Meier 
plot of the time from randomization to the pri-
mary outcome (Fig. S3).
The duration of patient stay in the ICU or 
high-dependency unit did not differ significantly 
between the two groups, and the rates of clini-
cally significant pulmonary complications were 
also similar (Table 3). There were significantly 
more deaths in the restrictive-threshold group 
than in the liberal-threshold group (4.2% vs. 
2.6%; hazard ratio, 1.64; 95% CI, 1.00 to 2.67; 
P = 0.045). Table S8 in the Supplementary Appen-
dix shows the causes of death. Mortality at 30 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on July 23, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 372;11 nejm.org March 12, 2015 1003
Tr ansfusion after Cardiac Surgery
days was 2.6% in the restrictive-threshold group 
and 1.9% in the liberal-threshold group. Kaplan–
Meier curves are shown in Figure S4 in the Sup-
plementary Appendix. EQ-5D scores were similar 
in the two groups (Table S9 in the Supplemen-
tary Appendix). The rate of serious postoperative 
complications (excluding primary-outcome events) 
was 35.7% in the restrictive-threshold group and 
34.2% in the liberal-threshold group (Table S10 
in the Supplementary Appendix).
Type of Transfusion
Restrictive  
Transfusion Threshold  
(N = 1000)
Liberal  
Transfusion Threshold  
(N = 1003)
Odds Ratio 
(95% CI) P Value
number (percent)
≥1 Units of red cells transfused before randomiza-
tion — no. of patients (%)†
250 (25.0) 264 (26.3)
Units of red cells transfused after randomization‡
Total units transfused — no. 1494 2494
Median — no. 1.0 2.0
Interquartile range 0–2.0 1.0–3.0
Distribution — no. of patients (%) 0.58 (0.54– 0.62)§ <0.001
0 units 466 (46.6) 78 (7.8)
1 unit 193 (19.3) 341 (34.0)
2 units 152 (15.2) 262 (26.1)
3 units 66 (6.6) 141 (14.1)
4 units 50 (5.0) 62 (6.2)
≥5 units 73 (7.3) 119 (11.9)
Transfused red cells during entire index  
admission — no. of patients (%)¶
637 (63.7) 952 (94.9)
Other transfusions — no. of patients (%)¶
Fresh-frozen plasma 297 (29.7) 284 (28.3) 1.08 (0.88–1.33) 0.45
Platelets 376 (37.6) 362 (36.1) 1.08 (0.89–1.31) 0.42
Cryoprecipitate 99 (9.9) 102 (10.2) 0.99 (0.72–1.35) 0.95
Activated factor used — no. of patients (%)¶ 7 (0.7) 5 (0.5) 1.41 (0.45–4.45) 0.56
Human blood coagulation factor IX used — no. of 
patients (%)¶
52 (5.2) 48 (4.8) 1.21 (0.73–2.03) 0.46
Severe nonadherence — no. of patients (%)‖ 97 (9.7) 62 (6.2)
Any nonadherence — no. of patients (%)** 300 (30.0) 453 (45.2)
*  Additional details regarding total units of red cells transfused after randomization and other transfusions that were performed are provid-
ed in Table S5 and Figure S2 in the Supplementary Appendix. CI denotes confidence interval.
†  This category includes intraoperative transfusions (which were performed in 184 of 1000 patients [18.4%] in the restrictive-threshold 
group and in 180 of 1003 patients [17.9%] in the liberal-threshold group) and postoperative transfusions before randomization (which 
were performed in 98 of 1000 patients [9.8%] in the restrictive-threshold group and in 114 of 1003 patients [11.4%] in the liberal-threshold 
group).
‡  This category includes transfusions performed during a reoperation after randomization or after treatment had been discontinued.
§  This estimate is a risk ratio, rather than an odds ratio. The risk ratio reflects the comparison of any transfusion versus no transfusion. This 
statistic was calculated from an unadjusted logistic-regression model with a log-link function because a model adjusting for cardiac proce-
dure or center would not converge.
¶  This category includes transfusions that were performed before and those that were performed after randomization.
‖  Severe nonadherence changed the classification of a patient as having or not having received a transfusion — that is, a transfusion was 
not performed in a patient whose hemoglobin level fell below the assigned threshold or a transfusion was performed in a patient whose 
hemoglobin level was above the assigned threshold.
**  Any nonadherence includes instances such as red-cell transfusions performed outside the prescribed 24-hour window or 2 units given 
consecutively without the hemoglobin level being measured again.
Table 2. Transfusions.*
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Sensitivity and Subgroup Analyses
When additional acute kidney injury events, iden-
tified by means of routinely collected data on 
creatinine level, were included in the primary 
outcome, there was a trend toward higher risk in 
the restrictive-threshold group than in the liberal-
threshold group (odds ratio, 1.20; 95% CI, 1.00 
to 1.44; P = 0.04) (Table S11 in the Supplemen-
tary Appendix). A similar trend was seen when 
patients who received a transfusion before ran-
domization were excluded from the primary-
outcome analysis (odds ratio, 1.23; 95% CI, 0.97 
to 1.54; P = 0.08). When the primary outcome was 
restricted to serious events, there was no signifi-
cant difference between the two groups (odds 
ratio, 0.99; 95% CI, 0.77 to 1.27; P = 0.94) (Tables 
S11 and S12 in the Supplementary Appendix). A 
further sensitivity analysis showed no signifi-
cant heterogeneity among sites (P = 0.65) and no 
trend toward a null effect with increases in se-
vere nonadherence (Fig. S5 in the Supplementary 
Appendix). There was no indication of signifi-
cant heterogeneity with respect to the primary 
outcome according to subgroup (Fig. 2).
Costs
Mean costs associated with red-cell units were 
£287 ($479) in the restrictive-threshold group and 
£427 ($713) in the liberal-threshold group (P<0.001). 
Other cost components and total mean costs up 
to 3 months after surgery were similar in the two 
groups (£10,636 [$17,762] in the restrictive-thresh-
old group and £10,814 [$18,059] in the liberal-
threshold group) (Table S14 in the Supplemen-
tary Appendix).
Discussion
In the TITRe2 trial, we tested the hypothesis 
that the use of a restrictive threshold, as com-
pared with a liberal threshold, for the transfu-
sion of red cells after cardiac surgery in adults 
would reduce postoperative morbidity and costs. 
We observed no significant between-group dif-
ference with respect to the primary composite 
outcome. This finding cannot be explained by 
the possibility that the study did not have ade-
quate power, since the power of the study was 
greater than that planned because of the higher-
than-expected frequency of the outcome. There 
were also no significant differences in outcome 
according to hemoglobin threshold in prespeci-
fied subgroup analyses, a finding that is incon-
sistent with the view that the thresholds for he-
moglobin in red-cell transfusions should be 
adjusted according to the patient’s level of risk. 
More patients in the restrictive-threshold group 
than in the liberal-threshold group died (4.2% 
vs. 2.6%). There were no significant differences 
in other secondary outcomes, including total 
costs, between the two strategies.
Our results differ from those of observational 
analyses of transfusion in patients undergoing 
cardiac surgery,36 which have uniformly showed 
that red-cell transfusion is associated with an 
increased risk of death and other serious adverse 
outcomes. The difference is probably due to the 
fact that observational analyses are confounded 
by prognostic factors that influence the decision 
to transfuse red cells. In contrast, our results are 
consistent with findings of a Cochrane review of 
randomized, controlled trials involving surgical 
patients and critically ill patients,9 in which the 
clinical outcomes in patients who received trans-
fusions with restrictive thresholds for hemoglo-
bin level were similar to those in patients who 
received transfusion with liberal thresholds.
A restrictive threshold for transfusion is 
likely to be favored because it requires the use of 
fewer units of allogeneic red cells. However, the 
results of our secondary analyses create new 
Figure 1. Mean Daily Nadir in Hemoglobin Level.
I bars indicate standard deviations, which were calculated independently at 
each time point.
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uncertainty regarding the use of a restrictive 
threshold for transfusion after cardiac surgery. It 
is challenging to interpret the results of second-
ary analyses when several statistical tests are 
performed,37 but the higher frequency of death 
in the restrictive-threshold group, which per-
Outcome
Restrictive  
Transfusion Threshold  
(N = 1000)
Liberal  
Transfusion Threshold  
(N = 1003) Estimated Treatment Effect
Odds Ratio or 
Hazard Ratio 
(95% CI) P Value
Serious infection or ischemic event: 
primary outcome
Overall 331/944 (35.1) 317/962 (33.0) 1.11 (0.91–1.34)* 0.30
Infectious event† 238/936 (25.4) 240/954 (25.2) 1.02 (0.83–1.26)* 0.83
Sepsis 210/982 (21.4) 214/983 (21.8)
Wound infection 55/921 (6.0) 46/936 (4.9)
Ischemic event 156/991 (15.7) 139/991 (14.0) 1.16 (0.90–1.49)* 0.26
Permanent stroke 15/989 (1.5) 17/985 (1.7)
Myocardial infarction 3/987 (0.3) 4/981 (0.4)
Gut infarction 6/987 (0.6) 1/982 (0.1)
Acute kidney injury 140/989 (14.2) 122/989 (12.3)
Stage 1 49/989 (5.0) 40/989 (4.0)
Stage 2 39/989 (3.9) 35/989 (3.5)
Stage 3 50/989 (5.1) 46/989 (4.7)
Secondary outcomes
No. of hours in ICU or high- 
dependency unit‡
Median 49.5 45.9 0.97 (0.89–1.06)§ 0.53
Interquartile range 21.9–99.7 20.1–94.8
No. of days in hospital¶
Median 7.0 7.0 1.00 (0.92–1.10)§ 0.94
Interquartile range 5.0–10.0 5.0–10.0
All-cause mortality at 90 days 42/1000 (4.2) 26/1003 (2.6) 1.64 (1.00–2.67)§ 0.045
Clinically significant pulmonary  
complications
127/979 (13.0) 116/982 (11.8) 1.11 (0.85–1.45)* 0.45
All-cause mortality at 30 days 26/1000 (2.6) 19/1003 (1.9)
*  This value is an odds ratio.
†  Since the amount of missing data was greater than 5% (owing primarily to missing data on posthospital discharge), a 
separate treatment estimate was estimated for infections that occurred before hospital discharge (according to the 
rules regarding missing data outlined in the statistical analysis plan in the study protocol). For this treatment effect, we 
estimated an odds ratio of 1.07 (95% CI, 0.85 to 1.36; P = 0.55).
‡  The duration of stay in the intensive care unit (ICU) or high-dependency unit after randomization was 0 days for 63 pa-
tients in the restrictive-threshold group and 61 patients in the liberal-threshold group; data were censored for 23 pa-
tients in the restrictive-threshold group and 15 patients in the liberal-threshold group. In addition, 37 patients in the re-
strictive-threshold group and 32 patients in the liberal-threshold group had more than one admission to the ICU or 
high-dependency unit.
§  This value is a hazard ratio.
¶  The duration of hospital stay after randomization was 0 days for 4 patients in the restrictive-threshold group and 2 pa-
tients in the liberal-threshold group; data were censored for 25 patients in the restrictive-threshold group and 17 pa-
tients in the liberal-threshold group.
Table 3. Outcomes.
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sisted in sensitivity analyses (Table S11 in the 
Supplementary Appendix), is a cause for con-
cern. It is not clear in what way anemia that was 
attributable to the restrictive threshold may have 
resulted in an increased number of deaths. The 
difference in hemoglobin level between the 
groups was modest (1 g per deciliter), and an 
assessment of causes of death or of severe ad-
verse events that preceded death did not suggest 
a cause-and-effect relationship, although estab-
lishing a cause-and-effect relationship may have 
been an unrealistic expectation given the small 
number of deaths that occurred and given a 
medical setting (cardiac surgery) in which death 
typically occurs after a sequence of adverse 
events. A benefit from transfusion with a more 
liberal hemoglobin threshold was also suggested 
in two sensitivity analyses of the primary out-
come, one in which patients who had received a 
transfusion before randomization were excluded 
and one in which additional acute kidney injury 
events, as determined on the basis of serial data 
on creatinine levels, were included. These find-
ings seem to support a hypothesis that the use 
of a more liberal hemoglobin threshold may be 
beneficial in patients with a hemoglobin level of 
less than 9 g per deciliter after cardiac surgery.
This hypothesis is clinically plausible. The 
TITRe2 trial differs from previous large trials of 
transfusion thresholds in that all the partici-
pants had cardiovascular disease38,39; in addi-
tion, a substantial proportion of participants are 
likely to have been dependent on oxygen supple-
mentation in the immediate postoperative peri-
od.40,41 Therefore, patients undergoing cardiac 
surgery are often at the limits of their cardiovas-
cular reserve and may benefit from higher he-
moglobin levels. Such patients were excluded 
Figure 2. Subgroup Analyses.
The gray vertical lines represent the overall treatment estimate (solid line) and the 95% confidence interval (dashed lines) for the prima-
ry outcome as calculated for the entire analysis cohort. The sizes of the circles designating the point estimates reflect the sizes of the 
subgroups. The restrictive transfusion threshold for hemoglobin was less than 7.5 g per deciliter, and the liberal transfusion threshold 
was less than 9 g per deciliter. CABG denotes coronary-artery bypass grafting, COPD chronic obstructive pulmonary disease, GFR glo-
merular filtration rate, and LV left ventricular.
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from the only contemporary trial we could find 
that showed restrictive transfusion to be benefi-
cial, a trial that assessed transfusion thresholds 
in patients with acute upper gastrointestinal bleed-
ing.42 In contrast, a large trial involving patients 
with hip fracture,43 in which 63% of the partici-
pants had cardiovascular disease, showed no 
benefit from restrictive transfusion, and a more 
recent feasibility trial of transfusion thresholds 
in patients with unstable coronary disease (myo-
cardial infarction) showed a reduced risk of 
death among patients who received transfusions 
at a more liberal hemoglobin threshold.44 Pa-
tients with cardiovascular disease may represent 
a specific high-risk group for which more liberal 
transfusion thresholds are to be recommended. 
This hypothesis should be tested in future prag-
matic trials.
The main limitation of our trial was our in-
ability to keep health care staff unaware of the 
group assignments. However, the use of objective 
end points and the adjudication of end points by 
personnel who were unaware of the group as-
signments protected against detection bias. The 
nature of nonadherence to protocol differed ac-
cording to group but affected the overall trans-
fusion rate in only a small percentage of partici-
pants. This percentage was similar in the two 
groups. Another limitation was that prospective 
data collection failed to identify acute kidney 
injury events that were apparent on the basis of 
the routinely collected data on serial creatinine 
levels. We attribute this discrepancy to differences 
among centers in the baseline creatinine value 
used to define acute kidney injury.45 Finally, we 
cannot exclude the possibility that other transfu-
sion thresholds, or a wider differential between 
the two transfusion thresholds, could have altered 
the results.
In conclusion, the TITRe2 trial compared a 
restrictive transfusion threshold with a liberal 
transfusion threshold after cardiac surgery. The 
restrictive threshold was not superior to the lib-
eral threshold with respect to postoperative mor-
bidity or total costs.
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